Test Price
2,000 AED✅ Home Collection Available
JAK2 V617F, CALR & MPL Mutation Detection Profile in UAE | 2000 AED
Executive Summary & Core Metrics
The JAK2 V617F, CALR & MPL Mutation Detection Profile delivers a diagnostic sensitivity of 99.9% through ISO 15189-accredited multiplex real-time PCR and Sanger sequencing. It is the definitive molecular panel for confirming Philadelphia-negative myeloproliferative neoplasms. Our logistics include VIP mobile phlebotomy with a temperature-controlled cold chain for home collection, available daily from 8 AM to 11 PM. Post-test telephonic clinical guidance is included at no extra charge, and direct insurance billing verification can be obtained via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This molecular diagnostic panel identifies mutations in JAK2 (V617F), CALR, and MPL genes, which are central to the diagnosis and classification of essential thrombocythemia, polycythemia vera, and primary myelofibrosis. The methodology integrates multiplex real-time PCR for detection, Sanger sequencing for confirmation, and fragment analysis for precise genotyping. This combination enables differentiation between clonal and reactive conditions, informing prognosis and targeted therapy selection.
| Feature | Our Service | Alternative Method |
|---|---|---|
| Diagnostic Sensitivity | 99.9% | ~90–95% (RFLP-based JAK2 only) |
| Methodology | Multiplex Real-Time PCR + Sanger Sequencing + Fragment Analysis | ARMS-PCR or RFLP for a single mutation |
| Turnaround Time | Sample Mon by 11 AM → Report Saturday | 7–10 working days |
Physician Insight & Safety Protocols
Clinical Insight from Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA ID: 9294403: “This mutation panel is a cornerstone for diagnosing MPNs, but it must never be interpreted in isolation. Full clinical correlation with complete blood counts, bone marrow histology, and patient history is essential for accurate diagnosis and risk stratification. Always discuss results with your treating haematologist.”
Advisory Guidance
Do not discontinue any prescribed medication, including antiplatelet agents or cytoreductive therapy, without direct consultation with your physician. The test result does not replace ongoing clinical monitoring.
Exclusion Criteria & Emergency Red Flags
- Contraindicated: Severe thrombocytopenia (platelets <20,000/µL) or active bleeding diathesis – phlebotomy risk is elevated.
- Defer testing: Critically ill patients requiring immediate medical intervention should postpone elective molecular profiling.
- Pregnancy: Not an absolute contraindication, but interpretation of results may be altered; consult your obstetrician and haematologist.
🚨 Seek emergency care immediately if you experience uncontrolled bleeding, severe headache, vision changes, or sudden shortness of breath.
Patient FAQ & Clinical Guidance
1. What is the purpose of the JAK2, CALR & MPL mutation panel?
This panel detects mutations in three genes (JAK2 V617F, CALR, and MPL) that drive Philadelphia-negative myeloproliferative neoplasms. It confirms diagnosis, differentiates between essential thrombocythemia, polycythemia vera, and primary myelofibrosis, and guides risk stratification and targeted therapy decisions.
2. How is the sample collected and what preparation is required?
A standard venous blood draw into an EDTA lavender tube is required; no fasting is needed. You must complete the mandatory Genomics Clinical Information Requisition Form (Form 20) to aid variant interpretation. The sample must be kept refrigerated at 2–8°C and never frozen. Home collection via VIP mobile phlebotomy is available daily from 8 AM to 11 PM.
3. What is the turnaround time and how will I receive my results?
Samples collected by Monday 11 AM are processed and results reported by Saturday. Secure digital delivery is provided via encrypted email. A telephonic consultation with a clinical geneticist for interpretation is included at no additional charge.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Framework
All genetic data processing at DNA Labs UAE operates under the strict provisions of the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Our DHA-licensed facility (License No. 1143) in Dubai Healthcare City enforces encrypted data storage, role-based access controls, and regular audit compliance to ensure absolute confidentiality.
Clinical & Logistical Metadata
| Test Name | JAK2 V617F, CALR & MPL Mutation Detection Profile |
| Price (AED) | 2000 |
| Turnaround Time | 5–7 working days (Sample Mon by 11 AM → Report Saturday) |
| Sample Type / Matrix | Peripheral whole blood – EDTA lavender tube |
| Methodology Used | Multiplex Real-Time PCR + Sanger Sequencing + Fragment Analysis |
| ICD-10-CM Code | D47.1 (Chronic myeloproliferative disease), Z01.818 (Encounter for other special examination) |
| LOINC Code | 33951-2 (JAK2 mutation analysis) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians